Publications by authors named "Kelly Pendergrass"

Claim this Profile
F
First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.
Angelo Di Leo, Guy Jerusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass

Breast· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Denise A Yardley, Edward R Arrowsmith, Brooke R Daniel, Janice Eakle, Adam Brufsky, Kelly Pendergrass

Breast Cancer Res Treat· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
James B Bussel, David J Kuter, Louis M Aledort, Craig M Kessler, Adam Cuker, Kelly B Pendergrass

Blood· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Angelo Di Leo, Guy Jerusalem, Lubos Petruzelka, Roberto Torres, Igor N Bondarenko, Kelly Pendergrass

J Natl Cancer Inst· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.
Francine M Foss, Nelida Sjak-Shie, Andre Goy, Eric Jacobsen, Ranjana Advani, Kelly Pendergrass

Leuk Lymphoma· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.
Scott D Ramsey, Sean D Sullivan, Shelby D Reed, Ya-Chen Tina Shih, Ken Schaecher, Kelly Pendergrass

Oncologist· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
Sally Anne Garnett, Miguel Martin, Guy Jerusalem, Lubos Petruzelka, Roberto Torres, Kelly Pendergrass

Breast Cancer Res Treat· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
J Randolph Hecht, Tanja Trarbach, John D Hainsworth, Pierre Major, Elke Jäger, Kelly Pendergrass

J Clin Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Angelo Di Leo, Guy Jerusalem, Lubos Petruzelka, Roberto Torres, Igor N Bondarenko, Kelly Pendergrass

J Clin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Paul Goss, Igor N Bondarenko, Georgiy N Manikhas, Kelly B Pendergrass, Wilson H Miller

J Clin Oncol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
Kelly Pendergrass, Richard Hargreaves, Kevin J Petty, Alexandra D Carides, Judith K Evans

Drugs Today (Barc)· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis